Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
The FDA has issued generics giant Ranbaxy Laboratories with two warning letters, detailing “extensive deviations from US cGMP requirements” at the firm’s manufacturing plants in Dewas and Paonta Sahib, India.
MannKind’s inhaled insulin treatment, Technosphere, has met its study goal in the first of three Phase III trials, leading to Pfizer transferring its remaining Exubera patients to the treatment.
Formatech hopes its new formulation method, which solubilises compounds in micelles consisting of fatty acids or alcohols, will improve both the safety and bioavailability of pharmaceutical products.
A surge in research into novel drug delivery systems will occur as companies seek to differentiate their products in response to pressure from biosimilars, according to a publication from Frost & Sullivan.
Bilcare GCS, the clinical supplies arm of Indian packaging giant Bilcare, has considerably expanded its Phase III trial offering in an effort to provide drugmakers with a complete package.
Patient recruitment specialist Acurian has hit a major milestone in its business, with more than half of the entire US population of type 2 diabetics now opted into its database.
Artelis president Jose Castilo believes that the record MAb yield from CHO cells grown in its iCELLis bioreactor shows the platform could shift the paradigm for the "production of recombinant proteins.”
in-PharmaTechnologist.com's latest round-up of developments in pharmaceutical manufacturing features news of the world’s “biggest pharmaceutical allergen production unit”, Lentigen’s relocation and a cytotoxic robot.
Shifting clinical trial operations from Western markets to India can reap substantial benefits for sponsors in saved costs and time, according to KPMG’s just-published report India Pharma Inc.
Assay Depot, a new online marketplace which allows bench researchers around the world to choose and buy a broad range of drug discovery services, went live yesterday.
US drug delivery specialist MonoSol Rx says it has received USPTO patent rights to processes used in the manufacture of PharmFilm, its proprietary thin film drug delivery technology.
APP Pharmaceuticals has bought additional facilities at a site in Grand Island, New York seizing the opportunity created by Astellas Manufacturing’s decision to shift production of its dermatitis drug Protopic to Japan.
Australian proteomics fluorescence expert Fluorotechnics has agreed to buy The Gel Company as part of its strategy to cement itself as a world leader in protein electrophoresis.
Speculation is rife that Australia’s Amcor is one of several companies to have tabled bids for Rio Tinto’s $4.4bn (€3.1bn) Alcan Packaging division that serves the pharmaceutical, food and tobacco industries.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
Takeda Pharmaceutical has filed a lawsuit in an attempt to recoup $26.7m in damages, after it had to recall a product made by a contract manufacturing organisation (CMO).
India’s contract manufacturing market is expected to rocket forward over the next couple of years to reach a value of $2.46bn in 2010, according to a just-released report from KPMG.
Pharmaceutical major Bristol-Myers Squibb has signed another deal with outsourcing specialist Accenture, this time tapping the firm for IT and financial support services via a 10-year contract worth $550m.
A nanoparticle capable of carrying a soluble and insoluble drug has been created for the delivery of combination therapies, according to research published in Nature.
Quintiles Transnational Corp has announced an expansion of its operations in Singapore in order to meet what it described as “surging demand” in the Asia-Pacific region.
Drug development services company PharmaNet saw its share price slashed in half on Friday after downsizing its 2008 revenues and earnings forecasts for the second time this year.
CSL Biotherapies, part of Australia’s CSL group, has begun shipping the first of six million doses of its thimerosal-free vaccine Afluria to the US CDC ahead of this year’s flu season.
As the December 31 deadline for the removal of CFC albuterol inhalers in the US approaches, a new report by Kalorama Information forecasts big changes in the global $36bn (€26bn) a year respiratory products market.
The outsourcing of Phase I trials to India may be allowed by 2009-10 after the Central Drugs Standard Control Organisation (CDSCO) said it is considering changing its stance.
BioReliance has had to significantly expand its Rockville, US, facility and hire new staff in order to accommodate the growing demand for its genetic toxicology (GeneTox) testing services.
Drug discovery informatics and services provider, Tripos International, has agreed to buy Pharsight Corporation, a provider of software and strategic services for clinical drug development.
Parexel has trimmed back its earnings guidance for the first quarter of fiscal 2009 as it starts the process of integrating ClinPhone, which the company bought for £91m (€114m) last month.
GlaxoSmithKline’s head of North American operations, Chris Viehbacher, is to takeover as chief operating officer (CEO) at Sanofi-Aventis after he missed out on the top spot at GSK last year.
Companies have failed to provide the information needed under the USP’s new chapter regarding residual solvents, causing them to incorrectly file ANDAs, according to the Office of Generic Drugs (OGD).
The FDA has granted sNDA approval for Akorn’s IC-Green injection dye, which is the first lyophilised product manufacturered at the firm’s Decatur facility to gain such status.
Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Genevac, Lock and AdvantaPure.
Gene therapy could be advanced by a worm more commonly associated with causing a deadly parasitic disease, according to researchers presenting at the British Pharmaceutical Conference (BPC).
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme.
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
Beleaguered life science tools and services company MDS Inc, has recorded disappointing third quarter results, with revenues from its Analytical Technologies and MDS Pharma Services divisions missing forecasts.
eClinical specialist Phase Forward has added to its portfolio by purchasing interactive-response technology company Clarix for $40m in cash in a move aimed at toppling ClinPhone from its leading position in the sector.
The second round of bids for Elan Drug Technologies (EDT) is expected to be received by mid-September, with a sale price of up to $1.4bn mooted in press reports.
US fine and industrial chemicals specialist Aceto says that its expansion on the global stage, particularly in Europe and Asia, is starting to pay financial dividends.
Despite a decade-long build up, drugmakers are yet to wake up to the “no data, no market” mantra of the EC’s REACH legislation, according to SAFC’s marketing director Amanda Halford.
UK researchers have developed two synthetic molecules that coax stem cells to differentiate into either neurons or epithelial cells for use in drug discovery applications.
Tocris Bioscience has launched a new search facility that enables researchers to search for chemicals by the biological targets they work on, rather than the chemical name itself.
